A New Era for Surgical Robotics: How Larry Wood's Leadership and Q2 2025 Growth Signal Sustained Momentum at PROCEPT BioRobotics

The surgical robotics sector has long been a beacon of innovation in healthcare, but few companies have captured the imagination of investors and clinicians alike as effectively as PROCEPT BioRobotics. As the firm transitions to a new leadership era under Larry L. Wood, the implications for its trajectory—and the broader market for robotic-assisted urology—are profound. With Q2 2025 revenue surging 48% year-on-year to $79.2 million, the question is no longer whether PROCEPT can grow, but whether it can sustain this momentum in a competitive landscape increasingly defined by technological disruption.

The Strategic Case for Larry Wood

Larry Wood's appointment as CEO marks a calculated shift from innovation-driven leadership to operational and commercial excellence. With over 40 years in medical technology, including transformative roles at Edwards Lifesciences—where he spearheaded the adoption of transcatheter aortic valve replacement (TAVR)—Wood brings a proven playbook for scaling high-impact medical devices. His tenure at Edwards is particularly instructive: the TAVR market grew from niche to multibillion-dollar status during his leadership, driven by a combination of clinical validation, regulatory agility, and aggressive market penetration.

At PROCEPT, Wood inherits a company with a robust foundation. Under Dr. Reza Zadno's stewardship, Aquablation therapy for benign prostatic hyperplasia (BPH) became a global standard, with nearly 100,000 procedures performed. The HYDROS Robotic System, the only AI-powered platform for this indication, has demonstrated superior outcomes compared to traditional surgical methods, including shorter hospital stays and reduced complications. Wood's challenge—and opportunity—is to leverage his operational expertise to accelerate adoption in untapped markets, such as Asia-Pacific and Latin America, while expanding the platform's applications to prostate cancer.

Q2 2025 Revenue: A Barometer of Resilience

The pre-announced Q2 2025 revenue of $79.2 million, representing a 48% annual growth rate, is more than a headline—it is a testament to the company's ability to outpace macroeconomic headwinds. While the broader medical device sector has faced volatility due to reimbursement pressures and supply chain bottlenecks, PROCEPT's performance underscores the inelastic demand for its solutions. BPH, which affects 40 million men in the U.S. alone, is a chronic condition with no viable long-term alternatives to surgery, making Aquablation's adoption less susceptible to economic cycles.

Moreover, the company's financials reflect disciplined capital allocation. Over $600 million in capital raised under Zadno's leadership has been directed toward R&D, global commercial infrastructure, and strategic acquisitions, all of which position the firm to capitalize on its first-mover advantage. With Wood's arrival, investors can expect a sharper focus on margin expansion and shareholder returns, potentially unlocking untapped value in a company that trades at a discount to its peers in the surgical robotics space.

A Vision for the Next Frontier

Wood's public statements hint at an ambitious agenda. Beyond scaling Aquablation, he has emphasized the potential of AI-powered robotics to redefine urology care. The HYDROS system's ability to adapt to varying prostate sizes and surgeon experience levels suggests a broader applicability across complex procedures. Clinical trials for prostate cancer, already underway, could diversify the company's revenue streams and reduce reliance on BPH alone.

Yet the risks are not trivial. Competitors such as Olympus and Boston Scientific are investing heavily in robotic platforms, while regulatory scrutiny of AI-driven medical devices remains a wildcard. Wood's experience navigating these challenges at Edwards—where he balanced innovation with compliance—will be critical. Investors must also weigh the company's dependence on a single product line, which, while dominant in its niche, could limit long-term growth if alternative therapies emerge.

Investment Considerations

For investors, the key question is whether PROCEPT can replicate the TAVR playbook in urology. Wood's track record suggests a high probability of success, but execution will be paramount. The company's upcoming Q2 2025 earnings call on August 6, 2025, will provide critical insights into its near-term priorities and guidance for 2026.

In the short term, the stock's valuation appears attractive relative to its growth trajectory. With a forward P/E ratio of 25x and a P/S ratio of 10x, PROCEPT trades at a discount to industry averages, despite outperforming peers in revenue growth. A long-term hold is warranted for those comfortable with the sector's risks, particularly given the aging demographic trends that will sustain demand for urology solutions.

Conclusion

Larry Wood's leadership transition and Q2 2025 performance together signal a company poised for sustained growth in surgical robotics. By combining Wood's operational acumen with the clinical differentiation of its AI-powered platform, PROCEPT BioRobotics is well-positioned to cement its dominance in BPH and expand into adjacent indications. For investors, the next 12-18 months will be a litmus test of the company's ability to scale its innovation—and its CEO's vision—to transform global urology care.